Public-registry trials using Telitacicept 160mg that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy | RemeGen Co., Ltd. | IgA Nephropathy | PHASE2 | 8 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →